GSK sells liver disease drug candidate to Alfasigma for $690m
Alfasigma has agreed to buy the global rights to GSK’s experimental liver disease drug in a deal worth up to…
09 Mar 2026
Vinay Prasad to leave the FDA again
Vinay Prasad is once again set to depart from his role at the US Food and Drug Administration (FDA), after just eight months back at the helm of the agency’s…
09 Mar 2026
Sciwind secures China’s NMPA approval for Ecnoglutide injection
Sciwind Biosciences has received China’s National Medical Products Administration (NMPA) approval for its Ecnoglutide injection for chronic weight management. Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor…
09 Mar 2026
BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment
Bristol Myers Squibb (BMS) has received the US Food and Drug Administration (FDA) approval for Sotyktu (deucravacitinib), an oral selective tyrosine kinase 2 (TYK2) inhibitor, to treat adults with active…
06 Mar 2026
Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal
Alnylam Pharmaceuticals has forged a discovery collaboration worth up to $1.23bn with cardiovascular disease specialist, Tenaya Therapeutics. Through this partnership, Alnylam will harness Tenaya’s capabilities to identify up to 15…
06 Mar 2026
J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma
Johnson & Johnson (J&J) has announced the US Food and Drug Administration (FDA) approval for the combination of Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adults with relapsed…
06 Mar 2026
Liberate Bio gains licences for myeloid-specific CAR design patents
Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for myeloid cells, such as monocytes and macrophages. The licences sourced…